Ongoing Clinical Trials for Benign Neoplasm of Ureter
Currently, there is one ongoing clinical trial focused on improving surgical recovery for patients with benign neoplasm of the ureter and related upper urinary tract conditions. This trial is investigating different pain management strategies to enhance recovery after robot-assisted surgery.
Clinical trial locations
Study on Spinal Morphine, Intravenous Lidocaine, and Bupivacaine for Patients Undergoing Robot-Assisted Surgery for Kidney or Ureter Conditions
This trial is being conducted in Sweden and focuses on improving recovery after robot-assisted surgery for conditions affecting the upper urinary tract. The study includes patients with benign tumors of the kidney or ureter, as well as those with related conditions such as kidney stones and kidney reflux.
Who can participate:
- Adults scheduled for planned (non-emergency) robot-assisted surgery on the upper urinary tract
- Patients who can provide both written and spoken consent after receiving information about the study
- Both male and female participants are welcome
Who cannot participate:
- Patients with cancer or malignant tumors in the kidney or ureter
- Those with kidney stones
- Patients with renal reflux (a condition where urine flows backward from the bladder to the kidneys)
What the trial focuses on:
The main goal of this study is to determine whether different pain management strategies can improve recovery after surgery. Researchers are comparing the effectiveness of three different approaches: spinal morphine (a strong pain reliever injected into the spinal fluid), intravenous lidocaine (a numbing medication given through a vein), and a combination of bupivacaine with adrenaline (local anesthetics that help numb the surgical area and prolong pain relief).
The trial uses a patient-centered measurement called “Quality of Recovery 15” to assess how well patients are recovering. This scale evaluates various aspects of recovery, including pain levels and overall well-being, at different time points after surgery. Participants will be randomly assigned to receive one of these treatments without knowing which one they are getting, allowing researchers to compare the results objectively.
Investigational drugs being tested:
- Morphine: A powerful pain reliever administered into the space around the spinal cord to reduce pain and support recovery
- Lidocaine: A local anesthetic given intravenously to help manage pain and improve postoperative recovery
- Bupivacaine: A medication used to numb specific areas of the body, given as part of spinal pain relief to enhance recovery after surgery
The study monitors patients from the time they join the trial through 30 days after surgery, tracking pain levels, the need for additional pain medications, recovery quality, and any complications that may arise. The trial is expected to be completed by December 31, 2025.
Summary
This single ongoing trial represents an important effort to optimize surgical outcomes for patients with benign neoplasm of the ureter and related upper urinary tract conditions. Located in Sweden, the study takes a comprehensive approach to pain management during robot-assisted surgery, comparing three distinct anesthetic strategies: spinal morphine, intravenous lidocaine, and bupivacaine with adrenaline.
What makes this trial particularly valuable is its patient-centered focus on quality of recovery rather than simply measuring technical surgical success. By exploring different combinations of well-established pain medications in a new surgical context, the research aims to identify the most effective approach for helping patients recover more comfortably and quickly after this type of minimally invasive surgery.
The trial’s use of robotic-assisted techniques reflects modern surgical advances, while its focus on optimizing pain management addresses one of the most important aspects of patient experience during recovery.
